| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23004 |
| Drug |
Ropeginterferon alfa-2b |
| Brand |
Besremi® |
| Indication |
Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. |
| Rapid review commissioned |
20/01/2023 |
| Rapid review completed |
15/03/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ropeginterferon alfa-2b compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/03/2023 |
| Pre-submission consultation with Applicant |
03/05/2023 |
| Full submission received from Applicant |
20/07/2023 |
| Preliminary review sent to Applicant |
27/11/2023 |
| NCPE assessment re-commenced |
03/01/2024 |
